13F Holdings
中文EN

DCOY Decoy Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1615219 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-231.0%
TTM EPS YoY118.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-11,102.9%
ROA-222.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets48.3%
Debt / equity0.00x
Current ratio1.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.56x
Accruals ratio-98.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue———$0$1.84M
R&D expense$368,170$770,027$7.17M$15.84M$8.55M
SG&A expense$3.73M$4.96M$5.72M$7.14M$6.10M
Operating income-$12.61M-$5.73M-$12.89M-$31.84M-$12.81M
Income tax$0————
Net income-$12.52M-$5.58M-$12.54M-$31.61M-$12.77M
EBITDA-$12.61M-$5.73M-$12.88M-$31.83M-$12.79M
EPS (basic)-129.10-69.54-30.74-14.88-7.72
EPS (diluted)-129.10-69.54-30.74-14.88-7.72
Weighted avg. shares (diluted)96,96780,184408,0782.12M1.65M
Balance sheet
Cash & equivalents$10.71M$2.43M$5.90M$12.11M$29.21M
Receivables————$1.60M
Current assets$10.99M$2.99M$6.52M$14.52M$30.16M
PP&E, net$40,559$0——$7,880
Goodwill———$0$8.87M
Total assets$11.06M$3.02M$6.59M$14.65M$40.83M
Current liabilities$5.17M$1.51M———
Total liabilities$5.17M$1.51M$1.30M$4.27M$2.11M
Shareholders' equity$5.89M$1.51M$5.29M$10.38M$38.72M
Shares outstanding531,96896,077492,3042.26M1.81M
Cash flow statement
Operating cash flow-$4.83M-$4.53M-$12.85M-$17.60M-$10.20M
Capital expenditure$577,000$0——$0
Free cash flow-$5.40M-$4.53M——-$10.20M
Investing cash flow$764,735$0$0-$1.50M$0
Financing cash flow$12.34M$1.06M$6.64M$1.99M$28.30M
Depreciation & amortization$7,151$4,424$10,051$6,677$19,183
Stock-based compensation$219,058$273,730$524,838$796,803$559,044

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.